Fulton Bank Has Cut Johnson & Johnson (JNJ) Stake By $590,055; Myomo (NYSEAMERICAN:MYO) Shorts Down By 1.24%

Johnson & Johnson (NYSE:JNJ) Logo

Fulton Bank decreased Johnson & Johnson (JNJ) stake by 6.09% reported in 2017Q4 SEC filing. Fulton Bank sold 4,245 shares as Johnson & Johnson (JNJ)’s stock declined 9.21%. The Fulton Bank holds 65,471 shares with $9.15M value, down from 69,716 last quarter. Johnson & Johnson now has $339.78 billion valuation. The stock decreased 0.70% or $0.89 during the last trading session, reaching $126.66. About 7.74M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since April 22, 2017 and is uptrending. It has underperformed by 10.43% the S&P500.

Myomo Inc (NYSEAMERICAN:MYO) had a decrease of 1.24% in short interest. MYO’s SI was 1.18 million shares in April as released by FINRA. Its down 1.24% from 1.19 million shares previously. With 495,700 avg volume, 2 days are for Myomo Inc (NYSEAMERICAN:MYO)’s short sellers to cover MYO’s short positions. The SI to Myomo Inc’s float is 37.33%. The stock increased 11.39% or $0.41 during the last trading session, reaching $4.01. About 2.30 million shares traded or 194.10% up from the average. Myomo, Inc. (NYSEAMERICAN:MYO) has 0.00% since April 22, 2017 and is . It has underperformed by 11.55% the S&P500.

Myomo, Inc., a commercial stage medical robotics Company, provides expanded mobility solutions for patients suffering from neurological disorders and upper limb paralysis in the United States. The company has market cap of $49.69 million. The firm develops and markets MyoPro, a myoelectric elbow/wrist/hand orthosis that supports an impaired hands and arms of individuals due to a brachial plexus injury, stroke, spinal cord injury, traumatic brain injury, amyotrophic lateral sclerosis, multiple sclerosis, and other upper limb neuromuscular deficits. It currently has negative earnings.

Investors sentiment increased to 0.87 in Q4 2017. Its up 0.04, from 0.83 in 2017Q3. It is positive, as 35 investors sold JNJ shares while 884 reduced holdings. 143 funds opened positions while 654 raised stakes. 1.72 billion shares or 0.40% more from 1.71 billion shares in 2017Q3 were reported. First National Bank & Trust Sioux Falls, South Dakota-based fund reported 6,660 shares. Holt Advsr Ltd Com Dba Holt Prns Lp accumulated 25,050 shares. Endurance Wealth owns 38,233 shares or 0.86% of their US portfolio. Clark Capital Mgmt Gp reported 309,596 shares. Srb stated it has 1,382 shares. Visionary Asset Management Inc has 0.07% invested in Johnson & Johnson (NYSE:JNJ) for 1,880 shares. & Mgmt reported 3.4% of its portfolio in Johnson & Johnson (NYSE:JNJ). Foster & Motley has 1.35% invested in Johnson & Johnson (NYSE:JNJ) for 60,642 shares. Cobblestone Cap Ltd Liability Company New York invested in 101,981 shares or 1.42% of the stock. Cohen Mngmt holds 1.88% or 57,774 shares in its portfolio. State Farm Mutual Automobile Insur Co reported 37.88M shares. Dorsey Whitney Trust Ltd Liability has 2.85% invested in Johnson & Johnson (NYSE:JNJ). Kemper Master Retirement holds 1.07% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 13,500 shares. Atwood And Palmer accumulated 0.6% or 30,366 shares. Kcm Inv Advisors Limited Liability Co holds 2.16% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 264,353 shares.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson has $170.0 highest and $90 lowest target. $135.44’s average target is 6.93% above currents $126.66 stock price. Johnson & Johnson had 100 analyst reports since August 7, 2015 according to SRatingsIntel. Barclays Capital maintained Johnson & Johnson (NYSE:JNJ) on Wednesday, April 20 with “Overweight” rating. The company was maintained on Wednesday, October 19 by UBS. Argus Research maintained the stock with “Buy” rating in Wednesday, April 20 report. The stock has “Buy” rating by Leerink Swann on Wednesday, October 18. The firm has “Buy” rating by BMO Capital Markets given on Monday, July 10. Cowen & Co maintained the stock with “Buy” rating in Friday, October 6 report. Leerink Swann maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, April 18. Leerink Swann has “Buy” rating and $16000 target. The company was reinitiated on Monday, October 5 by Piper Jaffray. Barclays Capital maintained it with “Equal-Weight” rating and $148 target in Wednesday, October 18 report. On Friday, January 12 the stock rating was maintained by Wells Fargo with “Buy”.

Since February 15, 2018, it had 0 buys, and 1 sale for $20.17 million activity. Another trade for 155,342 shares valued at $20.17 million was made by Stoffels Paulus on Thursday, February 15.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart